OrbiMed’s BioNTech BNTX Stock Holding History

OrbiMed’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-103,000	Closed	-$12.2M	–	123
2024 Q3	$12.2M	Buy	+103,000	New	+$9.47M	0.22%	75
2023 Q1	–	Sell	-36,300	Closed	-$5.45M	–	128
2022 Q4	$5.45M	Buy	+36,300	New	+$5.59M	0.1%	93

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

OrbiMed's BNTX Position: Q4 2024 in Review

OrbiMed sold out of BioNTech (BNTX) in Q4 2024, closing a stake of 103,000 shares — an estimated $12.2M sold.

OrbiMed first reported a position in BNTX in Q4 2022 and held it in 2 quarters. The position peaked at $12.2M in Q3 2024. 303 funds tracked by Wall St. Rank hold BNTX as of Q4 2024.

OrbiMed reported no remaining BioNTech position as of Q4 2024 after selling out during the quarter.
OrbiMed sold 103,000 BioNTech shares in Q4 2024, an estimated $12.2M.
OrbiMed first reported a position in BioNTech in Q4 2022 and held it in 2 quarters.
OrbiMed's BioNTech position peaked at $12.2M in Q3 2024.
303 funds tracked by Wall St. Rank held BioNTech as of Q4 2024.

Based on OrbiMed's 13F filing for Q4 2024, filed 14 Feb 2025.